Review article

Diagnosis and Treatment of Transthyretin Cardiac Amyloidosis. Progress and Hope

Esther González-López,[a,b] Ángela López-Sainz,[a] and Pablo Garcia-Pavia[a,b,c,*]

[a] *Unidad de Insuficiencia Cardiaca y Cardiopatías Familiares, Servicio de Cardiología, Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain*
[b] *Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain*
[c] *Facultad de Medicina, Universidad Francisco de Vitoria, Madrid, Spain*

A B S T R A C T

Cardiac amyloidosis is an infiltrative disorder caused by extracellular protein deposition. Transthyretin is a proamyloidotic protein that produces one of the most frequent forms of cardiac amyloidosis, either through mutations or a wild-type form (previously known as senile amyloidosis). Until very recently, diagnosis of transthyretin amyloidosis (ATTR) was very uncommon and histological confirmation was mandatory, making diagnosis of ATTR a real challenge in daily clinical practice. Moreover, the specific therapeutic options to alter the clinical course of the disease were very limited. However, advances in cardiac imaging and diagnostic strategies have improved recognition of ATTR. In addition, several compounds able to modify the natural history of the disease are in the final phases of research, with promising results. Given that effective therapies are on the horizon, cardiologists should be well-versed in this disease and be familiar with its diagnosis and treatment. This review describes the broad clinical spectrum of ATTR in detail, as well as recent advances in the diagnosis and treatment of this condition.

© 2017 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved.

Diagnóstico y tratamiento de la amiloidosis cardiaca por transtiretina. Progreso y esperanza

R E S U M E N

La amiloidosis cardiaca es una enfermedad infiltrativa por depósito extracelular de proteínas. De las proteínas proamiloidóticas a nivel cardiaco, la transtiretina produce una de las formas más frecuentes de amiloidosis cardiaca, bien por mutaciones o bien en su forma natural (*wild-type*) conocida previamente como amiloidosis senil. Hasta muy recientemente, el diagnóstico de amiloidosis por transtiretina (ATTR) se producía en reducidas ocasiones y requería confirmación histológica, por lo que establecer el diagnóstico constituía un verdadero reto en la práctica clínica habitual. Además, las opciones terapéuticas específicas para alterar el curso clínico de la enfermedad eran muy limitadas. Sin embargo, avances en el campo de la imagen cardiaca y en la estrategia diagnóstica de la enfermedad están facilitando un reconocimiento creciente de la ATTR. De forma adicional, diversos compuestos capaces de modificar la historia de la enfermedad se encuentran en fases finales de investigación, con resultados prometedores. Dado que una terapia efectiva parece estar cada vez más próxima, se hace imprescindible que los cardiólogos conozcan esta patología en profundidad y estén familiarizados con su diagnóstico y tratamiento. En esta revisión se repasará detalladamente el amplio espectro clínico de la ATTR, así como los recientes avances en el diagnóstico y tratamiento de esta entidad.

© 2017 Sociedad Española de Cardiología. Publicado por Elsevier España, S.L.U. Todos los derechos reservados.

* Corresponding author: Unidad de Insuficiencia Cardiaca y Cardiopatías Familiares, Servicio de Cardiología, Hospital Universitario Puerta de Hierro, Manuel de Falla 2, 28222 Majadahonda, Madrid, Spain.
E-mail address: pablogpavia@yahoo.es (P. Garcia-Pavia).

INTRODUCTION

Amyloidosis is a deposition disease caused by extracellular accumulation of fibrils whose source consists of proteins with an unstable structure that fold, aggregate, and undergo deposition.[1] Such deposition can alter tissue structure and impair the function of various organs and systems.[2]

Amyloid fibrils are insoluble and proteolysis resistant and are typically stained by Congo red, showing intense yellow-green birefringence under polarized light.[3] More than 30 proteins can cause amyloid deposition, but only 5 cause significant deposition in cardiac tissue[1]:

- Light chains, which cause primary amyloidosis (AL).
- Transthyretin (TTR), which causes TTR amyloidosis (ATTR).
- Apolipoprotein A.
- Fibrinogen.
- Serum amyloid-protein A, which produces secondary amyloidosis.

Primary amyloidosis and ATTR are the most common forms of cardiac amyloidosis, the AL form being historically considered more common in developed countries.[3]

Most of the information on cardiac amyloidosis has been based on AL. However, although the number of patients with AL has remained stable, the number ATTR diagnoses has recently increased and it is now thought that ATTR may be much more prevalent than AL.[2]

Transthyretin amyloidosis has very often been the subject of misdiagnosis or significant delays until its correct diagnosis. Reasons include heterogeneity in its forms, need for histological confirmation, shortages of specialized equipment, and erroneous beliefs among some cardiologists that it is a rare disease without treatment options.[2,3]

However, these aspects are changing. Diagnosis has implications for patient management. Specific therapies have been developed that may delay or stabilize deposition and that are more effective in the early stages. Early diagnosis is therefore crucial. This review describes significant recent advances in the diagnosis and treatment of ATTR, offering hope for patients with this condition.

TRANSTHYRETIN CARDIAC AMYLOIDOSIS

Transthyretin is a tetrameric plasma protein responsible for transporting thyroxine and retinol-bound protein. It is primarily synthesized in the liver and secondarily in the choroid plexus and retinal pigment epithelium.[4]

Transthyretin tends to dissociate to dimers and monomers, which misassemble into fibrils and undergo deposition. Point mutations or the effect of age can increase this tendency, giving rise to the 2 clinical forms of ATTR: mutant (ATTRm) and wild-type (ATTRwt).

MUTANT TRANSTHYRETIN AMYLOIDOSIS

More than 120 mutations are currently known to cause ATTRm. These mutations exhibit an autosomal dominant inheritance pattern, with variable penetrance.[4] Because of its wide geographic diversity, it is difficult to establish the prevalence of ATTR, but it is considered to be a rare disease with a prevalence of less than 1/100 000 inhabitants[2] (Table 1).

The first TTR mutations were reported as familial amyloid polyneuropathy (or Andrade disease), and consequently ATTRm has until recently been considered a neurologic disease. However, recent findings show cardiac involvement in more than half of the cases.[3]

There is a strong genotype-phenotype correlation, with mutations being associated with purely neurologic disease or purely cardiac disease.[3] However, the division of ATTRm into cardiac or neurologic disease may be an oversimplification, as there is considerable overlap between the 2 clinical forms on the disease spectrum.

The Val30Met mutation (now known as Val50Met after 20 positions were added to the traditional mutation name in ATTRm) is the most frequent mutation worldwide and is endemic in Portugal, Japan, and Sweden. Its estimated incidence in Portugal is 1 per 538 inhabitants.[2] Mallorca (Spain) and Valverde del Camino (Huelva, Spain) are also considered to be areas in which ATTRm is endemic. The estimated prevalence in Mallorca in symptomatic patients is 3/100 000 inhabitants.[5]

The Val30Met mutation causes a predominantly neurologic condition with symmetric sensory-motor polyneuropathy, which begins in the lower limbs and follows an ascending pattern. It can be associated with dysautonomia with orthostatic hypotension, erectile dysfunction, urinary incontinence, and gastrointestinal symptoms. It typically begins at the end of the second or third decade of life, and up to 43% of the patients have cardiac involvement that is a frequent cause of death[4] (Table 1).

Of particular relevance is the Val122Ile mutation (p. Val142Ile), which is present in 3% to 4% of the North American black population.[3] Although its penetrance is incomplete,[3] this mutation has been associated with a 47% increased risk of developing heart failure (HF).[6] A recent study showed that Val122Ile amyloidosis was the fourth most common cause of HF in the British Afro-Caribbean population.[7] Although up to 30% of patients with this mutation may have features of mild neuropathy,[6] the clinical phenotype is usually similar to that of ATTRwt.[4] Val122Ile should not be considered a mutation exclusive to the black population, because it can also be present in the white population. For example, we have identified this mutation in 4 white Spanish families without black ancestry.

WILD-TYPE TRANSTHYRETIN AMYLOIDOSIS

Wild-type transthyretin amyloidosis was first described in 1876. It was formerly called senile amyloidosis, but its diagnosis in patients aged 40 to 60 years has rendered this term obsolete. Of interest, the earliest known case of this mutation was found in a 47-year-old American patient.[8]

The exact prevalence of ATTRwt remains unknown. However, studies suggest that it is underdiagnosed and that it may be the most frequent form of cardiac amyloidosis.[2,3] The following results support this hypothesis:

- In patients aged more than 80 years, the prevalence of TTR deposition is 25% at autopsy.[3]
- In patients with HF with preserved ejection fraction (HFpEF), moderate-severe TTR deposition is 5% at autopsy.[9]
- In patients aged more than 60 years admitted for HFpEF and left ventricular hypertrophy (LVH) $\geq$ 12 mm, our group recently found a prevalence of 13%.[10]

Table 1

Main Clinical and Diagnostic Characteristics of Mutant and Wild-Type Transthyretin Cardiac Amyloidosis

	ATTRwt	ATTRm
Prevalence	Unknown. Apparently very frequent	< 1:100 000
Genetic study	Absence of mutations in TTR	Mutation in TTR
Typical age at presentation	> 60 y	Variable according to causative mutation
Sex	Male predominance. 80% patients	Male predominance, with more aggressive phenotype
Extracardiac manifestations	• Carpal tunnel syndrome (33%-49%) • Lumbar spinal stenosis • Traumatic biceps tendon rupture (32%)	• Ascending bilateral sensory-motor polyneuropathy • Dysautonomia: orthostatic hypotension, diarrhea-constipation, erectile dysfunction • Eye involvement: glaucoma, intravitreal deposition, scalloped pupils
Cardiac impairment	Constant	Variable according to causative mutation
Cardiac output	• Heart failure (53%-86%) • Conduction disorders • AF (43%-67%) • Degenerative AoS	• Conduction disorders • Heart failure • Infrequent AF (10%)
Diagnostic techniques		
ECG	• Pseudoinfarct pattern (63%-66%) • Low voltage (22%-33%) • Sokolow LVH (6%-13%)	• Pseudoinfarct pattern (18%-69%) • Low voltage (2%-25%) • Sokolow LVH (3%-8%)
ECHO	• Moderate-severe hypertrophy • Mild-moderate depressed LVEF (30%)	• Moderate hypertrophy • LVEF, typically preserved
Cardiac MRI	• Late enhancement • Elevated native T_1 and EV	
^{99m}Tc DPD scintigraphy	• Grade 2-3	• Grade 0: asymptomatic carriers • Grade 1: initial cardiac involvement • Grade 2-3: significant cardiac involvement

AF, atrial fibrillation; AoS, aortic stenosis; ATTRm, mutant transthyretin amyloidosis; ATTRwt, wild-type transthyretin amyloidosis; ECG, electrocardiogram; ECO, echocardiogram; EV, extracellular volume; LVEF, left ventricular ejection fraction; LVH, left ventricular hypertrophy; TTR, transthyretin.

Unlike ATTRm, ATTRwt is a sporadic disease that typically begins after age 70 years.[4] It is mainly found in men, and published series have reported rates ranging from 89% to 98%.[11,12] However, in a recent series of patients diagnosed with ATTRwt in 2 hospitals (Madrid, Spain and Bologna, Italy), our group found that 20% were women. Furthermore, other autopsy studies have also suggested that ATTRwt in women may be more widespread than previously reported. Therefore female sex should not decrease clinical suspicion of ATTRwt (Table 1).[13]

Autopsy findings show that TTR deposition is dispersed in different organs in ATTRwt. However, deposition is much greater in the heart due to the cardiac tropism of TTR, and cardiac involvement is the main clinical manifestation.[4] Patients may present with symptoms of extracardiac TTR deposition such as lumbar canal stenosis, atraumatic rupture of the biceps tendon or "Popeye sign", and carpal tunnel syndrome (CTS)[3] (Figure 1). All these features may help to guide and promptly establish the diagnosis. CTS may accompany other amyloidosis subtypes, but it is more common in ATTRwt. Deposition may precede cardiac manifestations by several years.[6] It may be used as an indication in elderly patients with LVH, especially if they have bilateral CTS not associated with specific occupational activities and are in New York Heart Association functional class ≥ II (unpublished data).

DIAGNOSIS OF TRANSTHYRETIN AMYLOIDOSIS

Clinical Presentation

Amyloid can infiltrate any cardiac structure.[1] Typically, deposition increases ventricular wall thickness, which causes a gradual decrease in distensibility leading to severe diastolic dysfunction. ATTR has therefore traditionally been included as a cause of restrictive cardiomyopathy.

However, the clinical spectrum of ATTR is much broader and more heterogeneous. The most common symptom of ATTR is HF. As mentioned, a study published by our group in 2015 suggested that a protocol based on ^{99m}Tc-3,3-diphosphono-1,2-propanodi-carboxylic acid (^{99m}Tc-DPD) scintigraphy may be useful for the diagnosis of ATTRwt in a significant proportion (13%) of patients older than 60 years admitted for HFpEF.[10] Based on this result, ^{99m}Tc-DPD scintigraphy was included in the 2016 European guidelines on HF as a useful tool for the identification of patients with ATTR.[14] However, ATTR should not be suspected exclusively in patients with HFpEF because, as amyloid deposition advances the contractile function worsens, and consequently ATTR can be associated with different degrees of systolic dysfunction.

Transthyretin amyloidosis is a phenocopy of hypertrophic cardiomyopathy (HCM) and may be confused with it. A recent multicenter French study reported that 5% of patients with HCM have ATTRm.[15] However, our results are not in line with this high rate, which could be related to the large black population in France.

Cardiac conduction abnormalities may be the first manifestation of ATTR. Amyloid infiltration of the sinus and atrioventricular nodes[1] may indicate the need for pacemaker implantation (Table 1). The previously mentioned study conducted in Spain and Italy found that conduction disorders were the first manifestation of ATTRwt in 7% of patients with this disease.[13]

Atrial arrhythmias are also very common in patients with ATTRwt[13] (Figure 2A), and the first manifestation of the disease can be stroke.[4] In fact, the Mayo Clinic group recently suggested that ATTRwt should be ruled out in the setting of a diagnosis of non-valvular atrial fibrillation (AF) in elderly patients.[8] In contrast, AF is much less common patients with ATTRm (Table 1).

Finally, we note that ATTR and degenerative aortic stenosis can coexist in the same patient. In 2016, several studies drew attention

Figure 1. Signs and symptoms of transthyretin amyloidosis. A: nontraumatic rupture of the right biceps tendon ("Popeye sign"). B and C: staining with hematoxylin-eosin (B) and Congo red (C), both ×200, of carpal ligament sample showing dense collagen bundles with noncellular material. Courtesy of Dr Clara Salas Antón.

to this possibility, and a prospective study reported that ATTRwt had a prevalence of 6% in patients older than 65 years who underwent aortic valve replacement.[16] This study suggested that patients with both entities had a much worse postoperative prognosis than those without ATTRwt (mortality 50% vs 6.9% after a median follow-up of 2.3 years).[16] Another recent study with ^{99m}Tc-DPD scintigraphy in 43 patients with low-flow/low-gradient aortic stenosis identified 5 patients with ATTRwt

Figure 2. Diagnostic techniques in transthyretin cardiac amyloidosis (ATTR). A: electrocardiogram of a patient with wild-type transthyretin amyloidosis (ATTRwt), showing atrial fibrillation and pseudoinfarct pattern in inferior leads. B: echocardiogram of a patient with mutant transthyretin amyloidosis with Val30Met mutation, with marked concentric left ventricular hypertrophy and mild pericardial effusion. C: longitudinal regional strain of patient with ATTRwt, showing preserved values in the apical segment and depressed values in the basal and midventricular segments. D, ^{99m}Tc-DPD (^{99m}Tc-3,3-diphosphono-1,2-propanodicarboxylic acid) scan of a patient with ATTRwt, showing biventricular uptake superior to bone uptake, corresponding to Perugini grade 3.

(prevalence 12%).[17] Patients with severe aortic stenosis and ATTRwt share the same demographic profile, and the appropriate treatment for patients with both diseases is still to be determined.

Usefulness of Diagnostic Techniques

The diagnosis of ATTR is a challenge in daily clinical practice. Although electrocardiography and echocardiography play a role in diagnosis, new noninvasive techniques have acquired a key role in the assessment of patients with ATTR.

Electrocardiogram

The association between low voltage and cardiac amyloidosis has long been considered indisputable.[3] The most widely used criteria in clinical practice are QRS amplitude < 1 mV in all precordial leads or < 0.5 mV in all limb leads.[1] Although low electrocardiographic voltages in the setting of LVH should establish suspicion, prevalence in a contemporary series of ATTR was as low as 20% to 25%.[3,4,13] Prevalence also varies according to the criteria applied. For example, use of the Sokolow criterion (S wave in lead V_1 + R wave in lead V_5 or V_6 < 1.5 mV) can increase calculated prevalence to between 46% and 58%.[13] The ratio of left ventricular wall thickness to total QRS voltage has been recommended to better assess disparities between the results of the 2 techniques.[2,3] However, up to 20% of patients with ATTR can meet electrocardiographic criteria for LVH.[2,3]

In most series of patients with cardiac amyloidosis, the pseudoinfarct pattern is the most common electrocardiographic finding[2,3,13] (Figure 2A). Due to possible conduction system involvement, complete or incomplete bundle branch blocks are also common.[3]

Echocardiography

Although echocardiography is the cornerstone of the initial diagnosis of ATTR, no findings are specific.[3] Transthyretin amyloidosis has typically been associated with a normal or small left ventricle with concentric hypertrophy.[3] The 10th International Symposium on Amyloid and Amyloidosis held in 2004 established the echocardiographic criterion of heart disease due to AL in the absence of other causes of LVH as the presence of LVH with a cutoff of 12 mm for interventricular septal wall thickness.[4] This criterion was later extrapolated to other forms of amyloidosis (Figure 2B), which conferred a high degree of specificity but low sensitivity.

Although concentric LVH has been classically described, current series suggest that about 20% have asymmetric LVH.[13]

Despite the classic association between a normal or slightly decreased left ventricular ejection fraction (LVEF) and cardiac amyloidosis,[2] the LVEF range is highly variable.[8] In a recent study conducted at the Mayo Clinic, an LVEF < 50% was observed in almost half of the patients with ATTRwt,[8] whereas in our series an LVEF < 50% was observed in 37% of patients.[13] In addition, the use of LVEF in the assessment of systolic function in cardiac amyloidosis is limited, because slightly depressed values are already indicative of relevant cardiac disease. This limitation can be overcome by the use of tissue Doppler velocities, strain imaging, and myocardial contraction fraction, which have been proposed as more appropriate indices to assess cardiac function.[2]

Other classic echocardiographic signs are right ventricular hypertrophy, biatrial dilatation, mild pericardial effusion,

atrioventricular valve thickening, atrial septal wall thickening, and granular sparkling appearance of the myocardium.[3,6] However, because some of these features were observed in a highly selected series of patients in advanced stages of disease, not all of them have to be present to establish suspicion.[1]

Regional strain imaging is a very useful technique for the early diagnosis of patients with ATTR. In patients with ATTR, longitudinal strain is depressed in basal and midventricular segments but is preserved in apical segments[18] (Figure 2C). This typical pattern can be useful in the differential diagnosis of ATTR from other heart diseases.[4]

Biomarkers

There are fewer data on the role of the N-terminal prohormone of brain natriuretic propeptide (NT-proBNP) and troponin in ATTR than there is in AL.[4] The NT-proBNP levels in ATTR are typically lower than in AL,[4] reflecting 2 different pathophysiological mechanisms: direct light-chain toxicity in AL vs induced tissue damage by protofibrils in ATTR.

Recently, the Mayo Clinic group proposed a stratification system similar to that in force for AL. In a cohort of 360 patients with ATTRwt, both biomarkers were shown to be predictors of mortality. Stage III patients (NT-proBNP > 3000 pg/mL and troponin T > 0.05 ng/mL) had a median survival of 20 months, whereas stage I and II patients had a median survival of 66 months and 40 months (no biomarker or just 1 biomarker above the established cutoff points, respectively).

Cardiac Magnetic Resonance Imaging

Cardiac magnetic resonance imaging (CMRI) can be used to obtain structural and functional information and characterize the composition of myocardial tissue.[3] The CMRI is essential in the early identification of ATTR, and in its differential diagnosis from other heart disease.

The characterization of tissue by CMRI is based on the following features:

- Late enhancement: A global subendocardial pattern is virtually pathognomonic of cardiac amyloidosis, but is only present in about a quarter of patients. Other patterns, such as transmural (the most common) or patching, are also compatible (Figure 3). Despite its high sensitivity and specificity, it should be taken into account that there may be a possible absence of late enhancement (15% of patients) and, in our experience, a nonnegligible percentage of false negatives for technical reasons.[3] The transmural enhancement pattern is associated with worse prognosis and is an independent predictor of mortality.[19]
- Long T_1 times: T_1 mapping is a technique in which a quantitative myocardial signal is measured before (native T_1) or after contrast administration. Native T_1 times are very long in cardiac amyloidosis.[3] T_1 mapping does not require the administration of contrast and so can be used in kidney failure. T_1 times may even be abnormal before LVH is observed.[3] T_1 times are longer in ATTR than in HCM and controls (1097 ms $\pm$ 43 ms vs 1026 ms $\pm$ 64 ms vs 9.67 ms $\pm$ 34 ms, respectively; P < .0001), but are shorter than those in AL (1130 ms $\pm$ 68 ms; P = 0.01).[20]
- Contrast administration can be used to calculate extracellular volume (ECV) and assess increases of extracellular space. ECV values in cardiac amyloidosis are higher than in other heart disease, except in myocardial infarct zones.[21] In 2016, our group, in collaboration with other national centers, reported that ECV

Figure 3. Diversity of late enhancement patterns by cardiac magnetic resonance imaging in transthyretin amyloidosis. A and B: late enhancement sequences, 4-chamber plane and short axis at the mid level, respectively, of a patient with mutant transthyretin amyloidosis (ATTRm), showing diffuse pathological transmural gadolinium deposition. C and D: late enhancement sequences, 4-chamber and short-axis basal level, respectively, of patients with ATTRm showing pathological gadolinium deposition with a patched pattern, with lower inferoseptal and inferolateral basal focal area. E and F, late enhancement sequences, 4-chamber plane and short axis at the apical level, respectively, of patients with ATTRm, showing extensive pathological transmural deposition, except in basal and middle anterolateral segments. Courtesy of Dr Jesús González Mirelis.

quantification can identify cardiac involvement in ATTRm and, for the first time, correlated it with the degree of neurologic impairment, supporting the use of this technique in early diagnosis and tracking of ATTRm.[22]

Quantitative T_1 mapping and ECV calculation techniques can be very useful in ATTR for early diagnosis, clinical follow-up, and treatment response assessment (Figure 4).

Cardiac Scintigraphy

In the 1980s, observation of cardiac uptake of several bone diphosphonate tracers was histologically correlated to the presence of cardiac amyloidosis.[23] The mechanism of uptake is not well characterized, but it may be related to the calcium content of amyloid deposits.

An early study by the Bologna group using ^{99m}Tc-DPD found cardiac uptake in 15 patients with ATTR and its absence in 10 patients with AL, using a score based on biventricular uptake equal or superior to bone uptake (Perugini score)[24] (Figure 2D). Similar findings were subsequently reported by our group and others.[25] Mild uptake (score 1) and moderate uptake (score 2) can be found in 30% and 10% of patients with AL, respectively.[24]

Given its high sensitivity and specificity, this technique is extremely useful for establishing a diagnosis of ATTR and may show cardiac involvement even when echocardiography and MRI findings are still normal. In fact, after scintigraphy for oncologic or rheumatologic indications, incidental findings of ATTR are not uncommon.[26]

The Tc-DPD is not available in the United States, but similar results have been reported using ^{99m}Tc-PYP (pyrophosphate) imaging.[27]

Other radiotracers are currently under study. For example, ^{18}F-florbetapir, which has already been approved for brain beta-amyloid imaging,[4] has been studied in patients with AL and ATTR. The results show that ^{18}F-florbetapir can detect myocardial AL and ATTR deposits.[28] Although the available data were obtained in case studies[29] and the high cost of this radiotracer limits its use, several studies are underway on the potential advantage of its use over that of Tc-DPD as a screening technique for the 2 most common types of amyloidosis.

Invasive Diagnosis

The definitive diagnosis of ATTR is based on the histological demonstration of amyloid fibrils. Although there may be extra-cardiac deposition, the likelihood of demonstrating amyloid by histology varies by organ.[2] There are few studies on the cost-effectiveness of extracardiac biopsy (eg, abdominal fat, gingival, salivary gland, gastrointestinal) in ATTR, which is greater in ATTRm than in ATTRwt. However, a negative biopsy of a clinically unaffected organ does not exclude a diagnosis of ATTR.[4]

As in ATTRwt, endomyocardial biopsy is indicated in patients with no extracardiac involvement or with heart disease alone.[3,4] Endomyocardial biopsy is a low-risk procedure (especially in experienced centers) and sampling errors are unlikely.[6]

After histological confirmation of amyloidosis, which may sometimes require interpretation by trained personnel,[6] correct

Figure 4. T$_1$ mapping, before and after contrast, with modified look-locker inversion-recovery (MOLLI) in 3T cardiac magnetic resonance imaging in healthy control, patient with transthyretin amyloidosis, and patient with primary light-chain amyloidosis. A and B: native T$_1$ mapping and extracellular volume (EV), respectively, in a healthy control, showing normal values (EV = 0.214). C and D: native T$_1$ mapping and EV, respectively, in a patient with mutant transthyretin amyloidosis with neurologic damage and incipient cardiac involvement, elevated native T$_1$, and slightly elevated EV (0.361). E and F: native T$_1$ mapping and EV, respectively, in a patient with wild-type transthyretin cardiac amyloidosis, elevated native T$_1$, and very high EV (0.626), reflecting massive amyloid infiltration. Courtesy of Dr Jesús González Mirelis.

classification of the subtype is crucial.[4] Currently, classification depends on a combination of immunohistochemistry, genetic analysis, and proteomics:

- Immunohistochemistry is based on the use of specific antibodies against known amyloid proteins. Although the results of this technique are typically definitive, it is less sensitive in the recognition of light chains.[4]
- This limitation can be overcome by the use of mass spectrometry, which provides definitive results and is the criterion standard in the confirmation of the amyloid subtype.[2] Although this technique is only available in specialist centers, it is especially useful in inconclusive cases or in cases that are positive for several antibodies on immunohistochemistry, which in our experience occurs in about 20% to 30% of cases. [4]
- Because clinical or histological techniques cannot distinguish ATTRm from ATTRwt, genetic studies are recommended in all cases of ATTR. The finding of a causative mutation can be of importance for offering genetic counseling and follow-up to asymptomatic carriers, [4,30] who could benefit from forthcoming therapies that delay or even prevent the onset of the disease.[31]

Noninvasive Diagnosis

Until recently, histological studies were considered essential in the diagnosis of ATTR.[3] However, to facilitate diagnosis, in 2016 an international multicenter study proposed a new algorithm for the noninvasive diagnosis of ATTR.[32]

The study analyzed the results of 1217 patients. The presence of classic signs of cardiac amyloidosis using imaging techniques, grade 2 or 3 Tc-DPD/PYP uptake on scintigraphy, and the absence of a monoclonal protein had a specificity and positive predictive value for ATTR of 100%[32] (Figure 5).

A key feature this algorithm is the absence of a monoclonal protein that could cause AL on serum chain assay (Freelite, The Binding Site, UK) and on immunofixation electrophoresis of blood and urine. The presence of a monoclonal protein is an indication for endomyocardial biopsy to distinguish between ATTR and AL.[32] Up to 5% of the population aged more than 65 years have monoclonal gammopathy of undetermined significance.[2] In elderly individuals, a moderate increase in circulating light chains should not directly lead to a diagnosis of AL. It has been reported that up to 10% of elderly patients with ATTRwt and monoclonal gammopathy of undetermined significance in reference centers had previously received a misdiagnosis of AL.[3,33] A correct diagnosis is needed to avoid inappropriate chemotherapy. Of interest, our hospital has documented 2 cases of patients with multiple myeloma and concomitant ATTRwt on mass spectrometry.

TREATMENT OF TRANSTHYRETIN CARDIAC AMYLOIDOSIS

Treatment of patients with ATTR has 2 objectives: to provide medical support and, if possible, to stop or delay amyloid deposition by the use of specific treatments.

Medical Treatment

The following sections describe supportive cardiac care for patients with ATTR.

Figure 5. Diagnostic algorithm for patients with suspected cardiac amyloidosis. 99mTc-DPD scintigraphy grading system: grade 0, no cardiac uptake; grade 1, slight lower uptake than bone; grade 2, moderate uptake equal to bone uptake; grade 3, severe uptake superior to bone uptake. ACV, stroke; AL, primary light-chain amyloidosis; AoS, aortic stenosis; ATTR, transthyretin amyloidosis; ATTRm, mutant transthyretin amyloidosis; ATTRwt, wild-type transthyretin amyloidosis; CMRI, cardiac magnetic resonance imaging; ECG, electrocardiogram; HCM, hypertrophic cardiomyopathy; HF, heart failure; RCM, restrictive cardiomyopathy; TTR, transthyretin.

Management of Heart Failure

Euvolemia must be maintained in patients with cardiac amyloidosis. Diet and lifestyle measures are very important. Diuretics are key to the treatment of HF in ATTR. However, because excessive use of diuretics can lead to hypotension (frequently due to autonomic dysfunction) and worsen the clinical situation, especially in ATTRm, extreme care must be exercised in its management.

In the treatment of HF in ATTR, it must be taken into account that impaired diastolic dysfunction and reduced stroke volume lead to compensatory tachycardia to maintain cardiac output. Therefore, beta-blockers must be used with care and individualized for each patient. Standard practice is to remove them in the absence of difficulties in controlling heart rate. This approach is even more important, if possible, in ATTRwt because of the frequent presence of conduction disorders.[6] Calcium antagonists and digoxin can bind to amyloid fibrils and are therefore contraindicated in ATTR owing to the risk of toxicity even at therapeutic doses.[6]

In contrast to HF with systolic dysfunction due to other etiologies, there is no evidence in support of a prognostic benefit due to the use of beta-blockers, angiotensin-converting enzyme inhibitors, or angiotensin II receptor antagonists in cardiac amyloidosis. In fact, their use may lead to clinical worsening due to hypotension and low output: a recent publication has reported worse prognosis in ATTRm and a neutral effect in ATTRwt.[34]

Management of Atrial Arrhythmias

The management of AF in ATTR is a challenge. Maintaining long-term sinus rhythm is difficult. However, electrical cardioversion may be attempted because it can lead to clinical improvement.

Thromboembolic risk in patients with ATTR is very high. In addition, chronic amyloid infiltration can lead to mechanical atrial dysfunction, which may be the underlying cause of the development of atrial thrombus in some patients without AF. Anticoagulant therapy in ATTR should not be based on the $CHADS_2$-VASC score and should be standard therapy in AF. Bleeding events are less common than in AL, and so some hospitals recommend anticoagulant therapy in sinus rhythm patients if there is poor atrial function according to transmitral Doppler velocities. Although there are no comparative studies on the effectiveness of direct oral anticoagulants vs vitamin K antagonists, our hospital has administered direct oral anticoagulants to selected patients.

Role of Devices

Current recommendations for pacemaker implantation are the same in ATTR and the general population. However, some groups favor prophylactic implantation, especially in patients with ATTRm and conduction disorders.[35] We do not favor this preventative

strategy and have not found such a high rate of conduction disorders to warrant prophylactic implantation in patients with ATTRm.

The role of implantable cardioverter-defibrillator (ICD) use in ATTR is not well established. In a small series, ICD implantation did not significantly improve survival, although it had an appropriate effect in multiple patients during the first 2 years.[36]

Heart Transplantation

Heart transplantation has played a minor role in ATTR because ATTRm can involve various organs and ATTRwt typically affects elderly patients. However, the absence of extracardiac involvement in patients with ATTRwt makes them good candidates for the procedure. The literature provides examples of successful transplantation in patients younger than 70 years with ATTRwt or with ATTRm and predominant cardiac involvement.[4]

Specific Treatment of Transthyretin Cardiac Amyloidosis

At present, there is no approved therapy for the specific treatment of ATTR cardiac amyloidosis, although liver transplantation (TxH) alone or in combination with heart transplantation has been used in ATTRm since the 1990s as a way to eliminate the main source of precursor TTR.[4]

Liver Transplantation

The Familial Amyloidotic Polyneuropathy World Transplant Registry[37] reported that more than 2000 patients with ATTRm have undergone TxH in 20 countries.[4] Patients with the Val30Met mutation and a predominantly neurologic clinical picture have a survival rate of more than 50% at 20 years.[3] These promising results are based on strict patient selection according to age, type of mutation, and stage of the disease. The most commonly accepted indication for TxH is the combination of young age, the Val30Met mutation, and early stages of the disease.

However, the main limitations of this technique are the shortage of donors, the need for chronic immunosuppression, advanced age at the time of presentation, and worse results obtained in patients with mutations other than the Val30Met mutation.

In addition, the theoretical suppression of production of the mutated protein is counteracted by postimplantation progressive native TTR deposition,[4,6] whose mechanism is not completely understood. In fact, cardiac TTR deposition after TxH affects morbidity and mortality.

The need to better understand the pathogenesis of ATTR and the limitations of TxH has stimulated the development of several drugs.

These new compounds act at different points in the TTR amyloidogenesis cascade (Figure 6). Treatment will always involve reducing the precursor protein, although avoiding deposition and

Figure 6. Specific therapies in transthyretin cardiac amyloidosis and main targets. AntiSAP + CPHPC, antiserum amyloid P component + (R)-1-[6-[(R)-2-carboxy-pyrrolidin-1-yl]-6-oxo-hexanoyl]pyrrolidine-2-carboxylic acid; AOs, antisense oligonucleotides; EGCG, epigallocatechin-3 gallate; siRNA, small interfering RNA; TTR, transthyretin; TUDCA, tauroursodeoxycholic acid.

eliminating existing depositions will be equally important. Therefore, we believe that, in future, the approach to this disease will be in the form of combined treatment.

Suppression of Transthyretin Synthesis

Two research lines are underway on the inhibition of TTR liver expression: the use of small interfering RNA (siRNA) and the use of antisense oligonucleotide (AO) drugs.

- The siRNA are double-stranded RNA molecules that silence messenger RNA sequences by specifically binding to them, preventing protein formation. Patisiran (ALN-TTR02) has been found to reduce TTR production by 80%.[38] In patients with ATTRm, TTR reduction was 87%.[39] A phase 2 trial has shown promising results, demonstrating stable echocardiographic, functional, and analytical parameters at 12 months and 24 months.[40] The results of the phase 3 neurologic study in patients with ATTRm and a subanalysis of patients with cardiac involvement are expected in 2017 (Table 2). Another drug, revusiran (ALN-TTR01), is administered subcutaneously and differs from patisiran in the lipid nanoparticles that encapsulate siRNA. This drug was the subject of a phase III clinical trial in patients with ATTRm who have heart disease. The study was discontinued last year due to an unexpected increase in mortality in the treatment group (Table 2).
- The AOs are short strands of oligonucleotides that specifically bind to RNA, preventing translation and target protein synthesis.[4] ISIS-TTR$_{RX}$ is a subcutaneous AO, with demonstrated dose-dependent reductions in TTR values of 75% to 90% in healthy volunteers.[4] The phase III trial in patients with ATTRm and neurologic phenotype ended in March 2017 and its results are expected by the end of 2017. However, the US Food and Drug Administration postponed the initiation of a phase III trial in patients with ATTRwt and ATTRm with heart disease due to cases of severe thrombocytopenia in the neurologic study (Table 2). Since 50% of participants in the neurologic study had cardiac disease, the results of this cardiac substudy will determine if the phase III trial is resumed. On the other hand, there are preliminary data from an open-label phase II trial. In this study, 22 patients with ATTRwt and ATTRm with heart disease received a weekly injection of ISIS-TTR$_{RX}$. According to report, the safety profile of the drug is very favorable and the intermediate data on cardiac disease progression by CMR, NT-proBNP, and 6-minute tests are positive.[41]

Stabilization of transthyretin

Dissociation of the TTR tetramer into subunits is a crucial step in ATTR fibril formation. Diflunisal and tafamidis are 2 TTR stabilizers with demonstrated efficacy in ATTRm polyneuropathy.

- Tafamidis is an orally administered small molecule that binds to TTR at T4 binding sites by stabilizing the protein and preventing its dissociation. Following publication of the results of a randomized double-blind trial in 125 patients with ATTRm and the Val30Met mutation in the initial stages of neurologic disease,[42] the European Medicines Agency approved its use in 2011 as an orphan medicinal product to delay neurologic progression. Recent data demonstrate the effectiveness of the drug to achieve neurologic stability in at least 60% of participants after more than 4 years of follow-up. To date, it has limited use in ATTR and cardiologic disease. A phase II study in 21 patients with ATTRm and different mutations showed that NT-proBNP and

echocardiographic parameters remained stable at 12 months.[43] Data from a 5-year cohort study confirmed that the drug was well tolerated at a dose of 20 mg, although few patients with ATTRwt remained stable at 3.5 years.[44] The ATTR-ACT trial is a 30-month phase III trial assessing the efficacy, safety, and tolerability of doses of 20 mg and 80 mg tafamidis vs placebo in 440 patients with ATTRm, ATTRwt, and HF. The primary endpoint includes hospital mortality and admission. Its results are expected in 2018.[3,27]

- Diflunisal is a nonsteroidal anti-inflammatory agent that stabilizes TTR molecules in vitro. It is not available in Spain, but can be medically requested from abroad for compassionate use. A phase III study of ATTRm in patients with predominantly neurologic involvement, more than half of whom had heart disease, found no significant differences in echocardiographic parameters over the study period (Table 2).[45] Its potential for gastrointestinal adverse effects, kidney failure, water retention, and hypertension make it unsuited to patients with heart disease. Evidence on diflunisal in patients with ATTR is very limited. There is one study, but it was limited by its having a nonrandomized single-center design with little follow-up and few patients (n = 13). There were no admissions for decompensated HF, but there was significant worsening of renal function.[46]
- More recently, a Spanish group demonstrated that tolcapone (an oral catechol-O-methyltransferase inhibitor used in the treatment of Parkinson disease) has the ability to bind in vitro to the TTR of patients with ATTRwt and Val122Ile with higher affinity than other stabilizers.[47]

Elimination of Amyloid Deposits

Amyloid deposits are very stable and it seems that the human organism has little ability to eliminate them. However, treatments that prevent new amyloid production, such as chemotherapy in AL, can gradually eliminate deposits at different organ-specific rates. Cardiac clearance is especially low and so far evidence of regression is scarce. Several molecules are currently under investigation to accelerate amyloid cardiac clearance in ATTR:

- Doxycycline (a commonly used antibiotic) disrupts the formation of amyloid fibrils. The synergistic effect of combined doxycycline and tauroursodeoxycholic bile acid (TUDCA), which is used in the treatment of liver disease, has been demonstrated to eliminate TTR deposits in animal models. A phase II study with 20 patients showed no cardiac or neurologic progression after 1 year of treatment with doxycycline/TUDCA, with an acceptable safety and tolerability profile.[4] Other phase II studies have attempted to confirm these findings using combined doxycycline/TUDCA, doxycycline/ursodeoxycholic acid, or doxycycline alone.[48–50] The preliminary results of one of these studies suggest a protective effect, with less worsening of cardiac function due to strain in the treatment group. Another of these studies obtained similar findings in 40 patients with ATTR: NT-proBNP, functional class, LVEF, and myocardial thickness parameters, among others, remained stable at 12 months (Table 2). Nevertheless, all these studies had a high dropout rate (35%-44%), mainly due to adverse effects, particularly sun hypersensitivity and gastrointestinal complaints (up to 30%).[48–50]
- The EGCG (epigallocatechin-3 gallate) is the most abundant catechin in green tea, and has been shown in vitro and in a murine model to inhibit amyloid formation and to eliminate existing deposits.[4] The CMRI showed that daily administration of

Table 2

Main Ongoing Clinical Trials in Transthyretin Cardiac Amyloidosis

Mechanism of action	Compound	Trial	Design	Patients (N) and ATTR subtype	Intervention	Primary endpoints	Situation/results
TTR synthesis suppression	Patisiran (ALN-TTR02)	NCT01961921	Phase II study, multicenter	27 ATTRm (11 heart involvement)	Patisiran 0.30 mg/kg IV every 3 wk for 2 y	Long-term safety. Secondary endpoints: effect on neurologic disorders and cardiac parameters	Well-tolerated drug, with similar safety profile in neurologic and cardiac phenotype Troponin I, NT-proBNP and echocardiographic data remained stable at 12 mo and 24 mo
		NCT01960348 (APOLLO)	Phase III, randomized, double-blind, placebo-controlled, multicenter	225 ATTRm with neurologic involvement	Patisiran infusion IV vs placebo 2:1	Changes in mNIS+7	Expected November 2017 Subanalysis of patients with predicted cardiac involvement
		NCT02510261	APOLLO extension study		Patisiran infusion IV vs placebo 2:1 for 52 wk	Safety and long-term adverse effects	Ongoing
	Revusiran (ALN-TTR01)	NCT02319005 (ENDEAVOUR)	Phase III, randomized, double-blind, placebo-controlled	206 ATTRm with heart involvement	Revusiran 500 mg 5 d, then weekly for 2 y vs placebo	Changes in 6-m walk test and in plasma TTR values	Discontinued due to increased mortality in the revusiran arm
	ISIS-TTR$_{RX}$	NCT01737398	Phase II/III, randomized, double-blind, placebo-controlled, multicenter	172 ATTRm with neuropathy; 50% concomitant heart involvement	ISIS-TTR$_{RX}$ 300 mg SC every 12 h for 1 wk, then weekly for 64 wk vs placebo	Changes in mNIS+7 and Norfolk quality of life questionnaire	Expected September 2017 Cases of severe thrombocytopenia and bleeding reported Analysis of echocardiographic parameters and NT-proBNP expected in patients without hypertension with LVH > 12 mm
		Treatment of TTR cardiomyopathy with TTR-specific antisense oligonucleotide	Phase II, open-label, nonrandomized	20 ATTRm with heart involvement and ATTRwt	ISIS-TTR$_{RX}$ 300 mg SC every 12 h/ wk	Echocardiographic parameters and cardiac MRI vs historic controls	No deterioration in strain and decreased LV mass of about 5% 6 patients completed 12 mo; 15 patients 6 mo; 1 patient TxC
		NCT02627820	Phase II, open-label, nonrandomized	50 ATTRwt	ISIS-TTR$_{RX}$ 300 mg SC every 12 h for 1 wk, then 1 wk for 18 wk	Changes in strain measured by speckle tracking	Cancelled without initiating patient recruitment
		Phase III study with ISIS-TTR$_{RX}$ for the treatment of TTR amyloid cardiopathy	Phase III, randomized, double-blind, placebo-controlled, multicenter	490 ATTRwt and ATTRm with heart involvement	ISIS-TTR$_{RX}$ 300 mg SC every 12 h for 1 wk, then weekly for 16 wk with placebo, then weekly for 24 mo	Death, TxC, or admission for cardiovascular causes	On hold
Stabilization of TTR	Tafamidis	NCT01994889	Phase III, randomized, double-blind, placebo-controlled, multicenter	441 ATTRwt and ATTRm with heart involvement	Tafamidis 20 mg or 80 mg orally every 24 h for 30 mo vs placebo	All-cause mortality and cardiovascular hospitalization	Ends February 2018
		NCT02791230	Extension Phase III NCT01994889	330 ATTRwt and ATTRm with heart involvement	Tafamidis 20 mg or 80 mg orally every 24 h for 60 mo	All-cause mortality and incidence of adverse effects	Expected December 2021
		NCT00935012	Phase II, open-label, efficacy and safety trial	31 ATTRwt or ATTRm p.Val122Ile with cardiac involvement	Tafamidis 20 mg orally	Safety and effectiveness	Ongoing until December 2021
	Diflunisal	NCT00294671	Phase III, randomized, double-blind, placebo-controlled, multicenter	130 ATTRm with neurologic phenotype (50% with cardiac involvement)	Diflunisal 250 mg orally every 12 h vs placebo over 24 mo	NIS+7 at 24 mo	NIS+7 diflunisal vs placebo 16.3 ($P < .001$) No reduction of ventricular thickness or strain in patients with heart involvement vs placebo

Table 2 (Continued)
Main Ongoing Clinical Trials in Transthyretin Cardiac Amyloidosis

Mechanism of action	Compound	Trial	Design	Patients (N) and ATTR subtype	Intervention	Primary endpoints	Situation/results
Elimination of deposits	Doxycycline + TUDCA/UDCA	NCT01171859	Phase II, open-label, nonrandomized, prospective	40 ATTR (25 ATTRm, 13 ATTRwt, and 2 domino liver transplant recipients)	Doxycycline 100 mg every 12 h + TUDCA 250 mg every 8 h for 12 mo, then 6 mo without therapy	Increase < 30% or < 300 pg/mL NT-proBNP	14 patients withdrew Adverse skin reactions, 16 patients 68% of the 25 evaluable patients fulfilled the primary endpoint Overall improvement in strain at 12 mo and worsening after 6 mo without therapy
		NCT01855360	Phase II, open-label, nonrandomized, prospective vs historic controls	30 Cardiac ATTR amyloidosis (27 ATTRwt and 3 ATTRm). Historic controls, 14 ATTRwt patients	Doxycycline 100 mg every 12 h + TUDCA 250 mg every 8h for 18 mo	Changes in longitudinal strain every 6 mo	22 patients completed the study and were evaluable Greater deterioration of strain in controls vs treatment group Increased NT-proBNP in treatment group; not measured in controls
		NCT01677286	Phase II, open-label, nonrandomized, prospective	25 Systemic amyloidosis (6 ATTRwt and 3 ATTRm)	Doxycycline 100 mg every 12 h for 12 mo	Drug safety Response of affected organs	Worsening of NT-proBNP and renal function No improvement in other parameters studied 60% of patients had skin complications and 30% withdrew due to skin or gastrointestinal problems
		NCT01171859	Phase II, open-label, nonrandomized, prospective	45 35 with heart involvement; 25 ATTRm; 5 ATTRm with TxH; 13 ATTRwt; and 2 domino liver transplant recipients	Doxycycline 100 mg every 12 h + TUDCA 250 mg every 8 h for 12 mo Subsequent follow-up phase without treatment for 6 mo	Drug response defined as a < 2-point increase in NIS-LL and an increase < 30% or < 300 pg/mL NT-proBNP at 12 mo	Cardiac response assessed in 25 patients 68% had cardiac response Increased NT-proBNP and deterioration of strain during follow-up without treatment High number of withdrawals due to adverse effects 14 withdrew in treatment phase and 5 discontinued in phase without treatment
		Effect of doxycycline + UDCA on ATTR	Phase II, open-label, nonrandomized, prospective	28 ATTR with cardiac involvement (27 ATTRm and 1 ATTRwt)	Doxycycline 200 mg/d for 4 wk, then suspended 2 wk, then UDCA 750 mg/d for 12 mo Subsequent follow-up phase without treatment for 6 mo	Changes in NT-proBNP and Kumamoto score	Only 14% completed the study and 36% completed 12 mo No changes in NT-proBNP at 6 mo and worsening at 12 mo Stable LVH Worsening of Kumamoto score at 12 mo
	EGCG	NCT01171859	Phase II, open-label, nonrandomized, prospective	25 ATTRwt	600 mg, EGCG for 12 mo	Changes in ECHO and cardiac MRI (n = 14)	Decreased LV mass 6% by cardiac MRI (P = 0.03) LVEF, myocardial thickness, and MAPSE by ECHO unchanged
	AntiSAP + CPHPC	NCT03044353	Phase II, open-label, randomized	40 Cohort 1: cardiac ATTR amyloidosis Cohort 2: primary amyloidosis after 6 mo of chemotherapy	Anti-SAP + CPHPC monthly for 6 mo	Reduced amyloid burden by cardiac MRI and ECHO	Start in 2017

AntiSAP + CPHPC, antiserum amyloid P component + (R)-1-[6-[(R)-2-carboxy-pyrrolidin-1-yl]-6-oxo-hexanoyl]pyrrolidine-2-carboxylic acid; ATTRm, mutant transthyretin amyloidosis; ATTRwt, wild-type transthyretin amyloidosis; BNP, brain natriuretic peptide; ECHO, echocardiogram; EGCG, epigallocatechin-3 gallate; IV, intravenous; LV, left ventricle; LVEF, left ventricular ejection fraction; LVH, left ventricular hypertrophy; MAPSE, mitral annular plane systolic excursion; mNIS, Modified Neuropathy Impairment Score; MRI, magnetic resonance imaging; NIS, Neuropathy Impairment Score; NIS-LL, Neuropathy Impairment Score of the Lower Limbs; NT-proBNP, amino-terminal pro-brain natriuretic peptide; SC, subcutaneous; TTR, transthyretin; TUDCA, tauroursodeoxycholic acid; TxC, heart transplant; TxH, liver transplant; UDCA, ursodeoxycholic acid.

600 mg EGCG was associated with left ventricular mass stabilization in a group of 25 patients (Table 2).[51]

- The PRX004 is a monoclonal antibody that acts by binding to monomer-specific epitopes and misfolded TTR. It thus elicits elimination of deposits by activating phagocytosis.[52] The basis of its mechanism of action is similar to that of an antibody used in AL. Phase II studies on this antibody are showing promising results. A phase I-II trial of this new antibody is set to begin in 2017.

- Regardless of the type of amyloid precursor protein, all deposits contain serum amyloid component P (SAP). Using this molecule as a target, anti-SAP antibodies have been shown to elicit a macrophage-mediated and complement-dependent reaction that caused major elimination of visceral amyloid deposits in a murine model. The bis-D-proline compound CPHPC can neutralize plasma SAP, and co-administration with anti-SAP IgG allows the antibody to reach SAP-containing deposits in tissue.[53] A phase I study published in 2015 demonstrated elimination of hepatic deposits in 15 patients with systemic amyloidosis without cardiac involvement, with few adverse effects.[53] A phase II study of patients with ATTR cardiac amyloidosis and AL is set to begin in 2017 (Table 2).

CONCLUSIONS

Transthyretin cardiac amyloidosis is diagnosed with increasing frequency. ^{99m}Tc-DPD scintigraphy and CMRI are examples of techniques that can be used for the simple and early identification of patients with ATTR.

Several ATTR-specific drugs are currently in the final phases of research. Therefore, we believe that ATTR cardiac amyloidosis will soon be considered a treatable entity rather than a fatal disease.

FUNDING

CONFLICTS OF INTEREST

E. González-López has participated as a speaker in activities organized by Pfizer. P. Garcia-Pavia has received payments as a speaker in activities organized by Pfizer and as a consultant to Alnylam, Prothena, and Pfizer. E. González-López, A. López-Sainz, and P. Garcia-Pavia declare that Pfizer has funded research projects by their institution.

REFERENCES

1. García-Pavía P, Tomé-Esteban MT, Rapezzi C. Amiloidosis. También una enfermedad del corazón. *Rev Esp Cardiol.* 2011;64:797–808.
2. Rapezzi C, Lorenzini M, Longhi S, et al. Cardiac amyloidosis: the great pretender. *Heart Fail Rev.* 2015;20:117–124.
3. Maurer MS, Elliott P, Comenzo R, Semigran M, Rapezzi C. Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis. *Circulation.* 2017;135:1357–1377.
4. Gertz MA, Benson MD, Dyck PJ, et al. Diagnosis, prognosis, and therapy of transthyretin amyloidosis. *J Am Coll Cardiol.* 2015;66:2451–2466.
5. Reinés JB, Vera TR, Martín MU, et al. Epidemiology of transthyretin associated familial amyloid polyneuropathy in the Majorcan area: Son Llàtzer Hospital descriptive study. *Orphanet J Rare Dis.* 2014;9–29.
6. Dungu JN, Anderson LJ, Whelan CJ, Hawkins PN. Cardiac transthyretin amyloidosis. *Heart.* 2012;98:1546–1554.
7. Dungu JN, Papadopoulou SA, Wykes K, et al. Afro-caribbean heart failure in the United Kingdom: cause, outcomes, and ATTR V122I cardiac amyloidosis. *Circ Heart Fail.* 2016;9:e003352.
8. Grogan M, Scott CG, Kyle RA, et al. Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system. *J Am Coll Cardiol.* 2016;68:1014–1020.
9. Mohammed SF, Mirzoyev SA, Edwards WD, et al. Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction. *JACC Heart Fail.* 2014;2:113–122.
10. González-López E, Gallego-Delgado M, Guzzo-Merello G, et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. *Eur Heart J.* 2015;36:2585–2594.
11. Pinney JH, Whelan CJ, Petrie A, et al. Senile systemic amyloidosis: clinical features at presentation and outcome. *J Am Heart Assoc.* 2013;2:e000098.
12. Connors LH, Sam F, Skinner M, et al. Heart failure resulting from age-related cardiac amyloid disease associated with wild-type transthyretin: a prospective, observational cohort study. *Circulation.* 2016;133:282–290.
13. González-López E, Gagliardi C, Dominguez F, et al. Clinical characteristics of wild-type transthyretin cardiac amyloidosis: disproving myths. *Eur Heart J.* 2017. http://dx.doi.org/10.1093/eurheartj/ehx043.
14. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur Heart J.* 2016;37:2129–2200.
15. Damy T, Costes CB, Hagège AA, et al. Prevalence and clinical phenotype of hereditary transthyretin amyloid cardiomyopathy in patients with increased left ventricular wall thickness. *Eur Heart J.* 2016;37:1826–1834.
16. Treibel TA, Fontana M, Gilbertson JA, et al. Occult transthyretin cardiac amyloid in severe calcific aortic stenosis: prevalence and prognosis in patients undergoing surgical aortic valve replacement. *Circ Cardiovasc Imaging.* 2016;9:e005066.
17. Longhi S, Lorenzini M, Gagliardi C, et al. Coexistence of degenerative aortic stenosis and wild-type transthyretin-related cardiac amyloidosis. *JACC Cardiovasc Imaging.* 2016;9:325–327.
18. Quarta CC, Solomon SD, Uraizee I, et al. Left ventricular structure and function in transthyretin-related versus light-chain cardiac amyloidosis. *Circulation.* 2014;129:1840–1849.
19. Fontana M, Pica S, Reant P, et al. Prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac amyloidosis. *Circulation.* 2015;132:1570–1579.
20. Fontana M, Banypersad SM, Treibel TA, et al. Native T1 mapping in transthyretin amylodosis. *JACC Cardiovasc Imaging.* 2014;7:157–165.
21. Sado DM, Flett AS, Banypersad SM, et al. Cardiovascular magnetic resonance measurement of myocardial extracellular volume in health and disease. *Heart.* 2012;98:1436–1441.
22. Gallego-Delgado M, González-López E, Muñoz-Beamud F, et al. El volumen extracelular detecta la amiloidosis cardiaca y está correlacionado con el deterioro neurológico en la amiloidosis familiar relacionada con la transtiretina. *Rev Esp Cardiol.* 2016;69:923–930.
23. Sobol SM, Brown JM, Bunker SR, Patel J, Lull RJ. Noninvasive diagnosis of cardiac amyloidosis by technetium-^{99m}-pyrophosphate myocardial scintigraphy. *Am Heart J.* 1982;103:563–566.
24. Perugini E, Guidalotti PL, Salvi F, et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using ^{99m}Tc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. *J Am Coll Cardiol.* 2005;46:1076–1084.
25. De Haro-del Moral FJ, Sánchez-Lajusticia A, Gómez-Bueno M, García-Pavía P, Salas-Antón C, Segovia-Cubero J. Papel de la gammagrafía cardiaca con ^{99m}Tc-DPD en la discriminación del subtipo de amiloidosis cardiaca. *Rev Esp Cardiol.* 2012;65:440–446.
26. Longhi S, Guidalotti PL, Quarta CC, et al. Identification of TTR-related subclinical amyloidosis with ^{99m}Tc-DPD scintigraphy. *JACC Cardiovasc Imaging.* 2014;7:531–532.
27. Bokhari S, Castaño A, Pozniakoff T, Deslisle S, Latif F, Maurer MS. ^{99m}Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. *Circ Cardiovasc Imaging.* 2013;6:195–201.
28. Park MA, Padera RF, Belanger A, et al. ^{18}F-florbetapir binds specifically to myocardial light chain and transthyretin amyloid deposits: autoradiography study. *Circ Cardiovasc Imaging.* 2015;8:e002954.
29. García-González P, Cozar-Santiago MP, Maceira AM. Amiloidosis cardiaca detectada mediante PET/TC con ^{18}F-florbetapir. *Rev Esp Cardiol.* 2016;69:1215.
30. García-Pavía P, Avellana P, Bornstein B, et al. Abordaje familiar en la amiloidosis cardiaca hereditaria por transtiretina. *Rev Esp Cardiol.* 2011;64:523–526.
31. García-Pavía P, Muñoz-Beamud F, Casasnovas C; Grupo de Estudio y Tratamiento de la Polineuropatía Amiloidótica Familiar por Transtiretina (GETPAF-TTR). Recomendaciones para el diagnóstico y tratamiento de la polineuropatía amiloidótica familiar por transtireina. *Med Clin (Barc).* 2015;145:211–217.
32. Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. *Circulation.* 2016;133:2404–2412.
33. Lachmann HJ, Booth DR, Booth SE, et al. Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. *N Engl J Med.* 2002;346:1786–1791.
34. Aus dem Siepen F, Hein S, Bauer R, Katus HA, Kristen AV. Standard heart failure medication in cardiac transthyretin amyloidosis: useful or harmful? *Amyloid.* 2017;24(sup1):132–133.

35. Algalarrondo V, Dinanian S, Juin C, et al. Prophylactic pacemaker implantation in familial amyloid polyneuropathy. *Heart Rhythm.* 2012;9:1069–1075.

36. Hamon D, Algalarrondo V, Gandjbakhch E, et al. Outcome and incidence of appropriate implantable cardioverter-defibrillator therapy in patients with cardiac amyloidosis. *Int J Cardiol.* 2016;222:562–568.

37. World Transplant Registry and Domino Liver Transplant Registry [Accessed 16 May 2017]. Available at: http://www.fapwt.org.

38. Coelho T, Adams D, Silva A, et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. *N Engl J Med.* 2013;369:819–829.

39. Suhr OB, Coelho T, Buades J, et al. Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study. *Orphanet J Rare Dis.* 2015;10:109.

40. Adams D, Coelho T, Conceicao I, et al. Phase 2 open-label extension (OLE) study of patisiran for the treatment of hereditary ATTR (hATTR) amyloidosis: 24-month safety and efficacy in subgroup of patients with cardiac involvement. *Eur J Heart Fail.* 2017;19(Suppl 1):19.

41. Benson MD, Ackermann EJ, Monia BP. Treatment of transthyretin cardiomyopathy with a TTR specific antisense oligonucleotide (IONIS-TTR$_{Rx}$). *Amyloid.* 2017;24 sup 1:134–135.

42. Coelho T, Maia LF, Martins da Silva A, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. *Neurology.* 2012;79:785–792.

43. Merlini G, Planté-Bordeneuve V, Judge DP, et al. Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis. *J Cardiovasc Transl Res.* 2013;6:1011–1020.

44. Maurer MS, Grogan DR, Judge DP, et al. Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes. *Circ Heart Fail.* 2015;8:519–526.

45. Berk JL, Suhr OB, Obici L, et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. *JAMA.* 2013;310:2658–2667.

46. Castaño A, Helmke S, Alvarez J, Delisle S, Maurer MS. Diflunisal for ATTR cardiac amyloidosis. *Congest Heart Fail.* 2012;18:315–319.

47. Sant'Anna R, Gallego P, Robinson LZ, et al. Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity. *Nat Commun.* 2016;7:10787.

48. Berk JL, Ruberg FL, Pawar S, et al. Doxycycline treatment of amyloidosis: a phase II study. In: *The XVth International Symposium on Amyloidosis.* Jul 2016.

49. Wixner J, Pilebro B, Lundgren HE, Olsson M, Anan I. Effect of doxycicline and ursodeoxycholic acid on transthyretin amyloidosis. *Amyloid.* 2017;24(sup1):78–79.

50. Obici L, Perlini S, Palladini G, et al. A phase II study of doxycycline plus tauroursodeoxycholic acid in transthyretin amyloidosis. In: *The XVth International Symposium on Amyloidosis.* Jul 2016.

51. Aus dem Siepen F, Bauer R, Aurich M, et al. Green tea extract as a treatment for patients with wild-type transthyretin amyloidosis: an observational study. *Drug Des Devel Ther.* 2015;9:6319–6325.

52. Higaki JN, Chakrabartty A, Galant NJ, et al. Novel conformation-specific monoclonal antibodies against amyloidogenic forms of transthyretin. *Amyloid.* 2016;23:86–97.

53. Richards DB, Cookson LM, Berges AC, et al. Therapeutic clearance of amyloid by antibodies to serum amyloid P component. *N Engl J Med.* 2015;373:1106–1114.